Phenomix CEO Mark Bagnall discusses the reasons for GLP-1 failure and why it’s common for patients to stop taking the medication.
Mark Bagnall
Advertisement
Mark Bagnall is CEO of Phenomix.
Articles by Mark Bagnall
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The New Era of U.S. Pharmaceutical Pricing: From Policy Upheaval to Strategic Adaptation
2
Pfizer and BioNTech Pause Covid Vaccine Study Following Low Enrollment Totals
3
FDA Approves Foundayo Under National Priority Voucher Program
4
President Trump Imposes 100% Tariffs on Branded Pharmaceuticals
5